STCube to Attend ESMO 2025... Clinical Competitiveness Highlighted by BTN1A1 Research Achievements

STCube is strengthening its presence on the global academic stage by showcasing the development achievements of its BTN1A1-targeted immuno-oncology drug, Nelmastobat. Following the presentation of its non-small cell lung cancer research results at the World Conference on Lung Cancer (WCLC) last month, the company will also present clinical results at the European Society for Medical Oncology (ESMO) and the Society for Immunotherapy of Cancer (SITC).

On October 1, STCube announced that it will present two abstracts related to Nelmastobat at ESMO, which will be held in Berlin, Germany, from October 17 to 21.

This opportunity is significant as it academically demonstrates the clinical value and differentiated therapeutic potential of the novel immuno-oncology target BTN1A1 in patients with colorectal cancer and non-small cell lung cancer.

The first abstract, titled "BTN1A1-Targeted Immunotherapy Enhances the Efficacy of Standard Treatments in Non-Small Cell Lung Cancer and Colorectal Cancer," evaluates combination strategies with BTN1A1 inhibitors using patient-derived organoids (PDOs) and zebrafish models.

The second abstract is titled "BTN1A1 H-Score and Multiplex Biomarker Analysis Predicting Clinical Benefit of Nelmastobat and Capecitabine Combination Therapy: Phase 1b/2 Study in Metastatic Colorectal Cancer." Soo Hyun Lee, a professor of oncology at Korea University Anam Hospital who led the investigator-initiated trial, is the lead author. The presentation will share results analyzing differences in progression-free survival (PFS) according to BTN1A1 expression levels (H-Score).

A representative from STCube introduced BTN1A1 as "a novel immune checkpoint expressed mutually exclusively with PD-L1, making it a strategic target to increase response rates in patients who are unresponsive or have developed resistance to existing immuno-oncology therapies." The representative added, "Through actual clinical trials, we continue to confirm that Nelmastobat has the potential to be a global first-in-class precision immunotherapy based on biomarkers."

STCube is currently conducting a phase 1b/2 clinical trial of Nelmastobat in combination with trifluridine-tipiracil (TAS-102) and bevacizumab in patients with BTN1A1-positive metastatic or recurrent colorectal cancer who have received third-line or later treatment. The trial is currently in the phase 2 dosing stage. The company is also preparing to initiate a phase 2 clinical trial of Nelmastobat in combination with docetaxel in patients with BTN1A1-positive advanced or metastatic non-small cell lung cancer who have received second-line or later treatment.

With participation in ESMO and SITC, STCube aims to promote its BTN1A1-targeted immuno-oncology drug development strategy to the global academic community and actively expand discussions on global partnerships, including follow-up clinical development and licensing-out (L/O) agreements.

This content was produced with the assistance of AI translation services.